These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 28339824)

  • 1. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
    Banerjee A; Jakacki RI; Onar-Thomas A; Wu S; Nicolaides T; Young Poussaint T; Fangusaro J; Phillips J; Perry A; Turner D; Prados M; Packer RJ; Qaddoumi I; Gururangan S; Pollack IF; Goldman S; Doyle LA; Stewart CF; Boyett JM; Kun LE; Fouladi M
    Neuro Oncol; 2017 Aug; 19(8):1135-1144. PubMed ID: 28339824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
    Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
    Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.
    Fangusaro J; Onar-Thomas A; Poussaint TY; Wu S; Ligon AH; Lindeman N; Campagne O; Banerjee A; Gururangan S; Kilburn LB; Goldman S; Qaddoumi I; Baxter P; Vezina G; Bregman C; Patay Z; Jones JY; Stewart CF; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
    Neuro Oncol; 2021 Oct; 23(10):1777-1788. PubMed ID: 33631016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.
    Eckstein OS; Allen CE; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey B; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga J; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
    J Clin Oncol; 2022 Jul; 40(20):2235-2245. PubMed ID: 35363510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
    Chénard-Poirier M; Hansen AR; Gutierrez ME; Rasco D; Xing Y; Chen LC; Zhou H; Webber AL; Freshwater T; Sharma MR
    Invest New Drugs; 2024 Jun; 42(3):241-251. PubMed ID: 38483782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
    Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G
    Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the mitogen‑activated protein kinase kinase and protein kinase A pathways overcomes acquired resistance to Selumetinib in low‑grade glioma cells.
    Melotti L; Meco D; Battaglia A; Buzzonetti A; Martini M; Ruggiero A; Scambia G; Riccardi R
    Oncol Rep; 2021 Feb; 45(2):752-763. PubMed ID: 33416182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Dabrafenib in Pediatric Patients with
    Hargrave DR; Bouffet E; Tabori U; Broniscer A; Cohen KJ; Hansford JR; Geoerger B; Hingorani P; Dunkel IJ; Russo MW; Tseng L; Dasgupta K; Gasal E; Whitlock JA; Kieran MW
    Clin Cancer Res; 2019 Dec; 25(24):7303-7311. PubMed ID: 31811016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
    Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
    N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium.
    Vajapeyam S; Brown D; Ziaei A; Wu S; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Jones BV; Yeom KW; Onar-Thomas A; Dunkel IJ; Fouladi M; Fangusaro JR; Poussaint TY
    AJNR Am J Neuroradiol; 2022 Mar; 43(3):455-461. PubMed ID: 35210278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
    Bouffet E; Jakacki R; Goldman S; Hargrave D; Hawkins C; Shroff M; Hukin J; Bartels U; Foreman N; Kellie S; Hilden J; Etzl M; Wilson B; Stephens D; Tabori U; Baruchel S
    J Clin Oncol; 2012 Apr; 30(12):1358-63. PubMed ID: 22393086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.
    Geoerger B; Hargrave D; Thomas F; Ndiaye A; Frappaz D; Andreiuolo F; Varlet P; Aerts I; Riccardi R; Jaspan T; Chatelut E; Le Deley MC; Paoletti X; Saint-Rose C; Leblond P; Morland B; Gentet JC; Méresse V; Vassal G;
    Neuro Oncol; 2011 Jan; 13(1):109-18. PubMed ID: 20974795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
    Hubbard JM; Yin J; Schenk EL; Qin R; Reid JM; Strand C; Fiskum J; Menefee M; Lin G; Doyle LA; Ivy P; Erlichman C; Adjei A; Haluska P; Costello BA
    Invest New Drugs; 2022 Feb; 40(1):115-123. PubMed ID: 34515877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.
    Manley PE; Trippett T; Smith AA; Macy ME; Leary SES; Boklan J; Cohen KJ; Goldman S; Kilburn LB; Dhall G; Devin J; Herzog CE; Partap S; Fauchet F; Badreddine E; Bernard JP; Chi SN
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27217. PubMed ID: 29750396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
    Stathis A; Tolcher AW; Wang JS; Renouf DJ; Chen LC; Suttner LH; Freshwater T; Webber AL; Nayak T; Siu LL
    Invest New Drugs; 2023 Jun; 41(3):380-390. PubMed ID: 37040046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
    Su JM; Thompson P; Adesina A; Li XN; Kilburn L; Onar-Thomas A; Kocak M; Chyla B; McKeegan E; Warren KE; Goldman S; Pollack IF; Fouladi M; Chen A; Giranda V; Boyett J; Kun L; Blaney SM
    Neuro Oncol; 2014 Dec; 16(12):1661-8. PubMed ID: 24908656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
    Coleman RL; Sill MW; Thaker PH; Bender DP; Street D; McGuire WP; Johnston CM; Rotmensch J
    Gynecol Oncol; 2015 Jul; 138(1):30-5. PubMed ID: 25887099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory
    Kieran MW; Geoerger B; Dunkel IJ; Broniscer A; Hargrave D; Hingorani P; Aerts I; Bertozzi AI; Cohen KJ; Hummel TR; Shen V; Bouffet E; Pratilas CA; Pearson ADJ; Tseng L; Nebot N; Green S; Russo MW; Whitlock JA
    Clin Cancer Res; 2019 Dec; 25(24):7294-7302. PubMed ID: 31506385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
    Fouladi M; Stewart CF; Olson J; Wagner LM; Onar-Thomas A; Kocak M; Packer RJ; Goldman S; Gururangan S; Gajjar A; Demuth T; Kun LE; Boyett JM; Gilbertson RJ
    J Clin Oncol; 2011 Sep; 29(26):3529-34. PubMed ID: 21825264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of vemurafenib in children with recurrent or progressive BRAF
    Nicolaides T; Nazemi KJ; Crawford J; Kilburn L; Minturn J; Gajjar A; Gauvain K; Leary S; Dhall G; Aboian M; Robinson G; Long-Boyle J; Wang H; Molinaro AM; Mueller S; Prados M
    Oncotarget; 2020 May; 11(21):1942-1952. PubMed ID: 32523649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.